**Table 1.** Incidence numbers estimate of US patients with definite impact *TSC1* and *TSC2* alterations available for first-line therapy in 2030

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Definite Impact**  ***TSC1* Alterations** | | **Definite Impact**  ***TSC2* Alterations** | | | **Total** | |  |
| **Tumor Type** | **Incidence**a | **Estimated Number**  **of US Patientsb** | | **Incidencea** | **Estimated Number**  **of US Patientsb** | **Incidencea** | **Estimated Number**  **of US Patientsb** | |
| Bladder | 6.33% | 1772 | | 1.70% | 477 | 8.03% | 2249 | |
| Endometrial | 2.10% | 835 | | 1.22% | 487 | 3.32% | 1322 | |
| Ovarian | 1.85% | 197 | | 0.92% | 98 | 2.77% | 295 | |
| Kidney | 1.51% | 318 | | -- | -- | -- | -- | |
| Soft tissue sarcoma | 1.28% | 41 | | 1.71% | 55 | 2.99% | 96 | |
| Hepatobiliary | 1.27% | 445 | | 3.31% | 1157 | 4.58% | 1602 | |
| Melanoma | 1.14% | 197 | | 0.68% | 118 | 1.82% | 315 | |
| CRC | 0.99% | 157 | | 0.39% | 63 | 1.38% | 220 | |
| Thyroid | 0.83% | 170 | | -- | -- | -- | -- | |
| NSCLC | 0.77% | 1297 | | 1.16% | 1945 | 1.93% | 3242 | |
| Esophagogastric | 0.65% | 18 | | 1.46% | 41 | 2.11% | 59 | |
| Pancreatic | 0.57% | 344 | | -- | -- | -- | -- | |
| Breast | 0.41% | 20 | | 0.10% | 5 | 0.51% | 25 | |
| Cervix | -- | -- | | 0.71% | 808 | -- | -- | |

aThe proportion of patients with definite impact mutations (ie, mutations known to have a biological impact; this includes frameshift, nonsense, and splice-site mutations and deep deletions) was derived from the NIH NCI Genomic Data Commons Data Portal (NIH NCI Genomic Data Commons). bEstimated numbers were derived based on the total number of advanced cases of each disease type (Siegel at al. 2019; and Surveillance, Epidemiology, and End Results [SEER] database https://seer.cancer.gov/statistics/) and the proportion of patients with definite impact mutations (NIH NCI Genomic Data Commons). Estimates were calculated by applying tumor type–specific alteration incidence rates sourced from TCGA program to tumor type–specific SEER Program estimated newly diagnosed patient numbers for 2030. TGCA and SEER data were accessed September 27, 2021. CRC, colorectal carcinoma; NCI, National Cancer Institute; NIH, National Institutes of Health; NSCLC, non-small cell lung cancer; SEER, Surveillance, Epidemiology, and End Results; TCGA, The Cancer Genome Atlas.